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Introduction: The Fostair® 100/6 (BDP/FF) pressurized metered-dose inhaler, delivering 
an extrafine formulation, is licensed for asthma and COPD in the UK. However, its real-life 
effectiveness for COPD has not been evaluated. This study compared the clinical effective-
ness of BDP/FF against other licensed ICS/LABA combination inhalers: the Seretide® 
Accuhaler® (FP/SAL) and the Symbicort® Turbohaler® (BUD/FF).
Methods: A matched historical cohort study was conducted using records of patients with 
diagnostic codes for COPD from the Optimum Patient Care Research Database (OPCRD). 
Patients who had received BDP/FF as their first ICS/LABA were matched 1:1 with patients 
who had received FP/SAL or BUD/FF, resulting in two matched comparisons. Additional 
analysis was conducted on patients who had never had diagnostic codes for asthma. 
Noninferiority in terms of the proportion of patients with moderate/severe COPD exacerba-
tions on the different inhalers in the following year was assessed. Noninferiority was 
achieved if the upper CI limit were ≤1.2.
Results: This study included 537 and 540 patient pairs in the BDP/FF vs FP/SAL cohort and 
the BDP/FF vs BUD/FF cohort, respectively. The proportion of patients with COPD exacer-
bations in the BDP/FF group was not significantly different from either the FP/SAL (68.7% 
vs 70.2%, AOR 0.89, 95% CI 0.67–1.19) or BUD/FF group (68.5% vs 69.4%, AOR 0.79, 
95% CI 0.58–1.08). Noninferiority of BDP/FF in preventing COPD exacerbations was 
fulfilled in both comparisons. In patients without asthma, BDP/FF was also noninferior to 
BUD/FF (proportion with COPD exacerbations, 67.8% vs 64.7%, AOR 0.79, 95% CI 0.51– 
1.1997). Additionally, a significantly lower proportion of patients prescribed BDP/FF had 
COPD exacerbations than FP/SAL (64.8% vs 73.7%, AOR 0.64 95% CI 0.43–0.96).
Conclusion: Initiating ICS/LABA treatment of COPD with extrafine-formulation BDP/ 
FF was noninferior in preventing moderate/severe exacerbations compared to FP/SAL 
and BUD/FF.
Keywords: metered-dose inhaler, dry-powder inhaler, chronic obstructive pulmonary 
disease, treatment efficacy, cost-effectiveness
Plain-Language Summary
The Fostair® (BDP/FF) inhaler has been licensed for asthma and chronic obstructive 
pulmonary disease (COPD) treatment in the UK. The medicine is delivered as very small 
particles, which helps delivery to the lungs. However, how well BDP/FF works for COPD 
treatment has been studied only in controlled clinical trials, but not in real-life clinical 
practice settings. We aimed to assess how well BDP/FF prevents COPD exacerbations 
compared to other similar products licensed in the UK: Seretide® (FP/SAL) and 
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Symbicort® (BUD/FF). General practice records stored in the 
Optimum Patient Care Research Database (OPCRD) were used 
in this study. The proportion of patients with COPD exacerba-
tions in the year the inhalers were started were compared across 
the different groups. In patients prescribed BDP/FF, 68.7% 
experienced exacerbations compared to 70.2% prescribed FP/ 
SAL. In the other comparison, 68.5% and 69.4% of patients 
prescribed BDP/FF and BUD/FF, respectively, experienced 
exacerbations. Therefore, prescription of BDP/FF led to compar-
able prevention of COPD exacerbations compared to prescription 
of FP/SAL or BUD/FF. Furthermore, BDP/FF was associated 
with better outcomes than FP/SAL within the group of patients 
without a previous history of asthma (35.2% vs 26.3% without 
exacerbations).
Introduction
Chronic obstructive pulmonary disease (COPD) is charac-
terized by declining lung function associated with high 
morbidity and health-care burden.1 In the UK alone, an 
estimated 1.2 million people have COPD, with a much 
larger population remaining undiagnosed.2,3 COPD 
accounts for 1.4 million general practice (GP) consulta-
tions yearly and one in eight emergency attendances.4
Inhaled corticosteroid (ICS) is administered to reduce 
the risk of subsequent COPD exacerbation.5 Evidence 
from clinical trials has suggested efficacy of an ICS admi-
nistered in combination with a long-acting β-agonist 
(LABA) for patients with moderate/severe COPD.6,7 The 
Fostair® 100/6 (BDP/FF) pressurized metered-dose inha-
ler (pMDI) has been licensed for patients with severe 
COPD (Forced Expiratory Volume in 1 second [FEV1] 
<50% predicted normal) and a history of exacerbations 
who have significant symptoms, despite regular therapy 
with long-acting bronchodilators.8 Other licensed ICS/ 
LABA combination inhalers for COPD include the 
Seretide® Accuhaler® 500/50 (FP/SAL) dry-powder inha-
ler (DPI) and the Symbicort® Turbohaler® 200/6 and 400/ 
12 (BUD/FF) DPI. BDP/FF, FP/SAL, and BUD/FF were 
the most commonly used ICS/LABA combination inhalers 
in the UK at the inception of this study.
The extrafine formulation of BDP/FF results in greater 
deposition to smaller airways, allowing for lower dosage for 
similar effects, thus subsequently reducing potential side 
effects compared to non-extrafine inhaler formulations.9–12 
The efficacy of BDP/FF has been previously demonstrated in 
randomized controlled trials (RCTs). The FUTURE trial 
showed BDP/FF to be equivalent to FP/SAL in improving 
breathlessness scores and superior at improving FEV1 and St 
George’s Respiratory Questionnaire (SGRQ) scores, despite 
lower ICS dosage.13 Another trial also showed BDP/FF to be 
noninferior to BUD/FF in improving predose morning 
FEV1.11 Complementing the results from RCTs, a study in 
a real-life setting demonstrated BDP/FF to be noninferior to 
FP/SAL in preventing symptom exacerbation in patients with 
asthma at equal or lower dosage.14 However, there is a lack 
of studies investigating the effectiveness of BDP/FF in 
COPD patients. Investigation of the clinical effectiveness of 
each ICS/LABA may be beneficial in guiding treatment of 
COPD patients requiring an ICS/LABA combination inhaler.
The current study aimed to assess the noninferiority of 
initiating BDP/FF compared to FP/SAL and BUD/FF in 




This was a historical matched cohort study encompassing 
a 1-year baseline period prior to the index date for char-
acterization of patients for matching and a 1-year outcome 
period after the index date to identify outcomes (Figure 1). 
The index date was defined as the date of first prescription 
of a BDP/FF pMDI, FP/SAL DPI, or BUD/FF DPI.
Data Source
Data for this study were obtained from the Optimum Patient 
Care Research Database (OPCRD; www.opcrd.co.uk), 
which comprises medical records of >7 million patients 
from over 700 GP practices across the UK.15 The OPCRD 
is approved by the Health Research Authority of the UK 
National Health Service for clinical research use (Research 
Ethics Committee reference 15/EM/0150).
Medication Studied
ICS/LABA combination inhalers with sufficient data in the 
OPCRD at the inception of this study — BDP/FF, FP/SAL, 
and BUD/FF — were chosen for this study. The BDP/FF 
investigated in this study was Fostair® , an ICS/LABA com-
bination inhaler, containing 100 µg beclometasone dipropio-
nate and 6 µg formoterol fumarate per inhalation in a pMDI 
device.16 The FP/SAL investigated in this study was the 
Seretide®  Accuhaler®  500 DPI, containing 500 µg flutica-
sone propionate and 50 µg salmeterol xinafoate per inhalation 
in a DPI device.17 The BUD/FF investigated was the 
Symbicort®  Turbohaler® , containing either 200 µg budeso-
nide and 6 µg formoterol fumarate dihydrate (Symbicort 200/ 
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6) or 400 µg budesonide and 12 µg formoterol fumarate 
dihydrate (Symbicort 400/12) per inhalation in a DPI device.-
18,19 As the recommended dosage for BUD/FF is two puffs 
twice daily of 200/6 or one puff of 400/12, we assumed equal 
BUD/FF dosage in both groups and thereby combined them.
Inclusion Criteria
Inclusion and exclusion criteria and patient flow are presented 
in Table 1. Patients included were ≥35 years old with COPD 
diagnosis confirmed by spirometry reading (FEV1/Forced 
Vital Capacity [FVC] <0.7) and had at least one moderate to 
severe exacerbation within the 18 months prior to the index. 
They must also have had available data encompassing the 
entire baseline and outcome periods, had one or more pre-
scriptions of LABA, LAMA, or unlicensed ICS/LABA com-
bination inhaler in the 2 years prior to the index, and had 
received two or more prescriptions of the same licensed ICS/ 
LABA combination inhaler during the outcome period 
(including initial prescription). Patients were excluded if they 
were recorded in the database to be nonsmoking or if there 
were no documentation of smoking status.
Patients were included if they had postbronchodilator 
FEV1% predicted <55% at any time prior to index. As a 
typical bronchodilator response is around 12%, patients 
with FEV1% predicted of 55% are expected to reflect 
patients with trough FEV1 predicted of 50% (reflecting 
the indication for BDP/FF).
Alternative comparison groups were selected excluding 
patients who had ever had a diagnostic code for asthma. 
This alternative comparison group was selected to inves-
tigate patients who had been treated with ICS/LABA spe-
cifically for COPD and not for asthma.
Outcome Assessments
The primary outcome of this study was the proportion of 
patients with moderate/severe COPD exacerbations, 
defined as any of: 1) unscheduled respiratory related hos-
pital admission or A&E attendance, 2) acute OCS pre-
sc r ip t ions  (defin i t ion  p rov ided  in  the  on l ine  
supplementary material), or 3) antibiotic prescriptions 
with a respiratory consultation in the 1-year outcome 
period.
Matching
Patients on BDP/FF pMDI were matched 1:1 with patients 
on FP/SAL and patients on BUD/FF, resulting in two 
matched comparisons. Patients who had been prescribed 
more than one type of ICS/LABA combination inhalers on 
separate occasions were selected only once during the com-
parison. The selected index patient event was the prescription 
of BDP/FF to maximize the number of matched pairs. 
Variables for matching were selected based on the standar-
dized difference and bias potential on the proportion of 
patients with an exacerbation between the treatment arms 
and clinical relevance. The final matching variables consisted 
of age, smoking status, FEV1% predicted, and number of 
exacerbations during the baseline year. Patients in the addi-
tional analysis, excluding patients with an asthma diagnosis, 
were matched in the same manner.
Statistical Analysis
Based on a previous study,20 if there is a true difference in AOR 
in favor of BDP/FF compared to the standard difference of 1.2, 
552 patients in each group are required to be 80% sure that the 
upper limit of a one-sided 97.5% CI will exclude a difference in 
favor of the predefined noninferiority margin of 20%.
Analysis was performed with SPSS version 23, SAS 
version 9.3, Stata SE version 14 (StataCorp, College 
Station, TX, USA), and Microsoft Office Excel 2013, as 
appropriate. Forest plots were generated using DistillerSR, 
an online tool from Evidence Partners.
Standardized mean difference (SMD) was calculated to 
quantify differences in baseline characteristics between 
Figure 1 Study design. 
Abbreviations: COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 second; BDP/FF, beclometasone and formoterol fixed-dose 
combination inhaler; FP/SAL, fluticasone propionate and salmeterol fixed-dosed combination inhaler; BUD/FF, budesonide and formoterol fixed-dose combination inhaler.
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compared treatment groups. An SMD ≥10 indicated suffi-
cient imbalance between the groups. SMD was utilized 
over p-value, as it is unaffected by sample size and is 
thus a better way to judge imbalance.
Primary Outcome Analysis
Adjusted proportions of patients within each treatment 
group recording any exacerbations in the outcome period 
was calculated using a generalized linear model with 
binomial distribution and logit link (logistic regression). 
Conditional logistic regression analysis was performed on 
the matched data set, taking matching into account for 
matched pairs.
Selection of factors for adjustment started with a model 
with exposure as the only explanatory variable. Variables 
were added one by one from the highest individual bias 
Table 1 Patient Flow and Inclusion and Exclusion Criteria
Patient 
Numbers
Inclusion/Exclusion Criteria Number 
Excluded


















































































Exclusion: duplicate patientsa BDP/FF 0 
FP/SAL 42 
BUD/FF 418
Notes: aPatients prescribed more than one ICS/LABA combination inhalers were assigned to the BDP/FF group.
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potential and kept in the model if there was a change in 
estimate of at least 2% relative to the prior model.
Noninferiority of BDP/FF pMDI was achieved if the 
upper bound of the 95% CI for odds of patients reporting 
COPD exacerbations was no more than 20% higher than 
the odds in the comparator groups (ie, the higher CI was 
<1.20). The noninferiority limit was predetermined based 
on a study assessing COPD as the outcome.21 Superiority 
of BDP/FF was then claimed if the proportion was sig-
nificantly lower at p=0.05.
Ethics
This study complied with all local and international laws and 
regulations, including ICH E6 guidelines for Good Clinical 
Practices, and governed by the Anonymous Data Ethics 
Protocols and Transparency (ADEPT) committee. This 
study was registered on the European Network of Centres 
for Pharmacoepidemiology and Pharmacovigilance 
(ENCePP) database (EUPAS9142), and the study protocol 
was approved by the ADEPT committee (ADEPT1016).
Results
Patient Demographics
After applying the inclusion and exclusion criteria, 549, 
3374, and 3001 patients prescribed BDP/FF pMDI, FP/ 
SAL DPI, and BUD/FF DPI respectively, were identified. 
Unmatched background demographics for these subjects are 
presented in Table S1 of the online supplementary material. 
Following matching, the final study population consisted of 
537 pairs of patients in the BDP/FF pMDI vs FP/SAL DPI 
cohort and 540 pairs in the BDP/FF pMDI vs BUD/FF DPI 
cohort. Matched baseline characteristics of both cohorts are 
presented in Table 2. Demographic characteristics were 
mostly balanced between groups in both pairs; however, 
fewer patients in the BDP/FF groups had been prescribed 
SABA compared to the FP/SAL (75.4% vs 83.2%) or BUD/ 
FF (75.6% vs 82.2%) groups. The BDP/FF group also had 
more patients with modified Medical Research Council 
(mMRC) dyspnea scores of 3 or 4 (indicating severe breath-
lessness) than the FP/SAL group (25.2% vs 21.3%), but 
fewer than the BUD/FF group (24.7% vs 25.8%). 
Proportions of patients who had moderate/severe COPD 
exacerbations were 91.4% and 91.1% in each matched 
cohort, respectively. The exploratory analysis cohort (sub-
jects without history of asthma diagnosis) consisted of 315 
and 314 pairs of subjects in the respective matched cohorts. 
Baseline characteristics for patients in the exploratory 
analysis cohort are presented in Table S2 of the online 
supplementary material.
Prevention of COPD Exacerbations
Patients with Asthma Diagnosis Included
In the BDP/FF vs FP/SAL matched pair, the proportions of 
patients who had at least 1 COPD exacerbation were 68.7% 
and 70.2% respectively (AOR 0.89; 95% CI 0.67–1.19). The 
proportions of patients in the BDP/FF vs BUD/FF pair were 
68.5% and 69.4% respectively (AOR 0.79; 95% CI 0.58– 
1.08). As the upper limits of the 95% CI in both pairs were 
lower than the pre-defined noninferiority margin of 1.2, BDP/ 
FF was noninferior to both FP/SAL and BUD/FF in prevent-
ing subsequent exacerbations (Figure 2). Unadjusted OR are 
provided in the online supplementary material (Table S3).
Patients with Asthma Diagnosis Excluded
Among patients who never had an asthma diagnosis, pro-
portions of those prescribed BDP/FF and BUD/FF who 
had at least one COPD exacerbation in the outcome period 
were 67.8% vs 64.7%, respectively (AOR 0.79, 95% CI 
0.51–1.1997), thus also fulfilling the noninferiority criter-
ion for prevention of COPD. However, in addition to being 
noninferior, BDP/FF was also superior to FP/SAL within 




In this real-life observational study, the Fostair® 100/6 
(extrafine formulation BDP/FF) pMDI was found to be 
noninferior to both the Seretide® Accuhaler® 500/50 (FP/ 
SAL) DPI and the Symbicort® Turbohaler® 200/6 (two 
puffs twice daily dose) and 400/12 (one puff twice daily 
dose) (BUD/FF) DPI in terms of the proportion of patients 
experiencing a COPD exacerbation within a year since 
treatment initiation.
To the best of our knowledge, this is the first study to 
evaluate the clinical effectiveness of BDP/FF pMDI com-
pared with other ICS/LABA combination inhalers for 
management of COPD within a real-life setting. This 
study adds evidence to the current literature, which has 
established the efficacy of extrafine formulation BDP/FF 
for the management of COPD via RCTs.11, 13, 22,23 The 
observed efficacy of BDP/FF may also be partly due to the 
extrafine formulation, which has been demonstrated to be 
advantageous over fine-particle ICS in both asthma24 and 
COPD.25
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Table 2 Matched Baseline Patient Characteristics










Sex Male 292 (54.4) 313 (58.3) 7.9 295 (54.6) 293 (54.3) 0.7
Age (years)a ≥35–<45 7 (1.3) 7 (1.3) 0 10 (1.9) 10 (1.9) 0
≥45–<55 39 (7.3) 39 (7.3) 41 (7.6) 41 (7.6)
≥55–<65 115 (21.4) 115 (21.4) 113 (20.9) 113 (20.9)
≥65 376 (70.0) 376 (70.0) 376 (69.6) 376 (69.6)
BMI (kg/m2) n (% not missing) 537 (100) 536 (99.8) 5.5 540 (100) 538 (99.6) 9.6
<18.5 30 (5.6) 31 (5.8) 30 (5.6) 30 (5.6)
≥18.5–<25 180 (33.5) 191 (35.6) 179 (33.1) 200 (37.2)
≥25–<30 192 (35.8) 179 (33.4) 193 (35.7) 171 (31.8)
≥30 135 (25.1) 135 (25.2) 138 (25.6) 137 (25.5)
Patient-reported smoking statusa Nonsmoker 19 (3.5) 19 (3.5) 0 17 (3.1) 17 (3.1) 0
Current smoker 224 (41.7) 224 (41.7) 227 (42.0) 227 (42.0)
Ex-smoker 294 (54.7) 294 (54.7) 296 (54.8) 296 (54.8)
Baseline SABA prescription(s) 0 132 (24.6) 90 (16.8) 23.9 132 (24.4) 96 (17.8) 18.9
1 38 (7.1) 36 (6.7) 38 (7.0) 43 (8.0)
2–4 82 (15.3) 110 (20.5) 81 (15.0) 93 (17.2)
5–10 141 (26.3) 169 (31.5) 145 (26.9) 173 (32.0)
≥11 144 (26.8) 132 (24.6) 144 (26.7) 135 (25.0)
SAMA/SABA combination prescriptions Yes 7 (1.3) 53 (9.9) 38.0 7 (1.3) 41 (7.6) 30.9
ICS combination-inhaler prescriptions 0 187 (34.8) 173 (32.2) 10.9 184 (34.1) 242 (44.8) 27.7
1 26 (4.8) 23 (4.3) 26 (4.8) 29 (5.4)
2–4 51 (9.5) 59 (11.0) 53 (9.8) 65 (12.0)
5–10 146 (27.2) 135 (25.1) 147 (27.2) 110 (20.4)
≥11 127 (23.6) 147 (27.4) 130 (24.1) 94 (17.4)
Total ICS dosage (µg BDP equivalent) 0–249 235 (43.8) 221 (41.2) 7.1 235 (43.5) 275 (51.0) 22.0
250–499 148 (27.6) 145 (27.0) 149 (27.6) 158 (29.3)
500+ 154 (28.7) 171 (31.8) 156 (28.9) 106(19.7)
LAMA prescriptions Yes 340 (63.3) 323 (60.1) 6.5 342 (63.3) 285 (52.8) 21.5
LABA prescriptions Yes 63 (11.7) 79 (14.7) 8.8 64 (11.9) 127 (23.5) 30.9
Maintenance OCS Yes 36 (6.7) 25 (4.7) 8.9 37 (6.9) 22 (4.1) 12.2
Asthma diagnosis everb Yes 218 (40.6) 197 (36.7) 8.0 220 (40.7) 230 (42.6) 3.8
Active anxiety/depression diagnosis Yes 134 (25.0) 123 (22.9) 4.8 135 (25.0) 105 (19.4) 13.4
Charlson Comorbidity Index 0–2 343 (63.9) 347 (64.6) 2.2 345 (63.9) 349 (64.6) 9.1
3–4 134 (25.0) 129 (24.0) 135 (25.0) 145 (26.9)
5+ 60 (11.2) 61 (11.4) 60 (11.1) 46 (8.5)
Baseline moderate/severe COPD exacerbationsa,c 0 46 (8.6) 46 (8.6) 0 48 (8.9) 48 (8.9) 0
1 159 (29.6) 159 (29.6) 162 (30.0) 162 (30.0)
2 139 (25.9) 139 (25.9) 138 (25.6) 138 (25.6)
3 75 (14.0) 75 (14.0) 75 (13.9) 75 (13.9)
4+ 118 (22.0) 118 (22.0) 117 (21.7) 117 (21.7)
Lowest percentage predicted FEV1
a <20% 24 (4.5) 24 (4.5) 0 24 (4.4) 24 (4.4) 0
20%–<30% 98 (18.2) 98 (18.2) 96 (17.8) 96 (17.8)
30%–<40% 159 (29.6) 159 (29.6) 161 (29.8) 161 (29.8)
40% –<55% 256 (47.7) 256 (47.7) 259 (48.0) 259 (48.0)
(Continued)
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The National Institute for Health and Care Excellence 
(NICE) guidelines for COPD recommend consideration of 
ICS/LABA in patients with features of asthma or a higher 
blood-eosinophil count.26 This study showed that in a real- 
life setting, BDP/FF has an advantage over FP/SAL in 
COPD patients without asthma.
Strengths and Weaknesses
The current study investigated the effectiveness of BDP/FF 
within a real-life observational setting. RCTs employ inclu-
sion and exclusion criteria to ensure high internal validity for 
the investigation of the investigational products’ efficacy at 
the cost of their external generalizability.27 Real-life studies 
complement RCTs by enabling investigation on a wider 
range of subjects, including those typically excluded in 
RCTs. Therefore, our results may be more representative of 
patients managed in real-life health-care practice.28 
Regardless, this study’s inclusion criteria reflected the popu-
lation of COPD patients indicated for BDP/FF, thus support-
ing the findings from previous RCTs with real-life 
evidence.7,11
Another strength of this study is the observation of 
outcomes of initiating ICS/LABA-combination inhalers 
over a 1-year outcome period. Therefore, any transient or 
seasonal changes that may have affected outcomes were 
minimized.
The limitation of this study is inherent to its nature as a 
historical study. Despite extensive quality control and 
validation, records collected in the OPCRD were not initi-
ally collected for research, but for routine clinical pur-
poses. As such, some degree of inaccuracy and 
incompleteness may be present. Also inherent to retro-
spective studies is the inability to control for potential 
confounders and variables not recorded in the database.
Table 2 (Continued). 










mMRC score n (% not missing) 317 (59.0) 310 (57.7) 19.9 315 (58.3) 267 (49.4) 17.2
mMRC 0 37 (11.7) 23 (7.4) 37 (11.7) 21 (7.9)
mMRC 1 105 (33.1) 121 (39.0) 106 (33.7) 101 (37.8)
mMRC 2 95 (30.0) 100 (32.3) 94 (29.8) 76 (28.5)
mMRC 3 66 (20.8) 52 (16.8) 64 (20.3) 61 (22.8)
mMRC 4 14 (4.4) 14 (4.5) 14 (4.4) 8 (3.0)
Notes: Numbers presented as n (%). SMD values >10 (indicating sufficient imbalance between comparison groups) are emphasized in bold. aMatching variable. bBased on 
presence of QOF diagnosis code for asthma. cOccurrence of any one of: 1) COPD-related unscheduled hospital admission/A&E attendance, 2) an acute course of oral 
steroid, or 3) antibiotics prescribed with lower respiratory consultation. 
Abbreviations: SMD, standardised mean difference; SABA, short-acting β-agonist; SAMA, short-acting muscarinic antagonist; LAMA, long-acting muscarinic antagonist; 
LABA, long-acting β-agonist; OCS, oral corticosteroid.
Figure 2 Odds ratios for COPD exacerbation between BDP/FF and FP/SAL or BUD/FF. 
Notes: aAdjusted for baseline ICS/LABA combination-inhaler prescriptions, baseline SABA prescriptions, baseline SAMA/SABA prescriptions, and active anxiety/depression. 
bAdjusted for theophylline prescription, ischemic heart disease diagnosis, and LTRA prescriptions. cAdjusted for SABA daily dose, ICS prescriptions, hypertension, and 
diabetes diagnosis. 
Abbreviations: POP, population size; OR odds ratio; LCL, lower confidence interval; UCL, upper confidence interval.
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After applying all inclusion and exclusion criteria, the 
number of matched pairs in both comparison groups (n=537 
and 540) fell short of the number required to be 80% sure 
that the upper limit of a one-sided 97.5% CI will exclude a 
difference in favor of the predefined noninferiority margin 
of 20%. However, the upper bound of the CIs of both 
comparison groups still fell under 1.20. We used different 
adjustment variables for each comparison pair in our ana-
lysis for the OR for COPD exacerbation. This was con-
ducted as each matched comparison pair was drawn from 
different patient populations. However, this may have 
included a risk of overfitting to our statistical models.
As data on medication usage were not captured in the 
OPCRD,29 the current study was unable to control completely 
for adherence to prescribed ICS/LABA in this study. It is well 
established that despite its impact on the outcome of inhaler 
treatment, poor adherence is common among asthma and 
COPD patients.30,31 Therefore, future observational studies 
evaluating the effectiveness of inhalers might consider stratify-
ing patients by their adherence to their prescribed ICS/LABA 
inhalers. A possible proxy for the measurement of adherence 
from clinical records includes medication possession ratio, 
defined as the ratio between the actual and expected number 
of medications prescribed.30–32
The current study was unable to account for proper use 
and handling of inhaler devices, which are vital for opti-
mal delivery of drugs to the lungs.33 Poor inhaler techni-
que is known to be very common among patients with 
COPD, especially in a real-life setting.34–36 Even though 
BDP/FF is now licensed with a DPI device, this study 
analyzed the real-world performance of an extrafine-for-
mulation BDP/FF pMDI. Regardless, this study shows that 
in a real-life setting, where imperfect inhaler-handling 
techniques might exist, in addition to the potential imper-
fect adherence to therapy, the BDP/FF pMDI was not 
inferior to FP/SAL or BUD/FF DPI.
Lastly, despite the noninferiority and superiority 
observed when comparing BDP/FF against BUD/FF and 
FP/SAL in the exploratory analysis group of patients with-
out asthma, further investigation is required, as this 
exploratory group was not sufficiently powered for a non-
inferiority analysis.
Future Studies
COPD is a complex disorder with multiple underlying 
phenotypes that may respond differently to therapy.37 In 
this study, we observed differential responses to BDP/FF 
compared to FP/SAL among COPD patients without 
asthma. Further investigation on the differential responses 
to FDC ICS/LABA by other phenotypic markers, such as 
peripheral blood eosinophil level is of interest.
The scope of our current study was limited to FDC 
ICS/LABA licensed for COPD in the UK at the time of 
this study’s conception. Future studies may be conducted 
to repeat our analyses for comparison of BDP/FF with 
other licensed ICS/LABA combinations, such as FF/ 
Vilanterol FDC (Relvar Ellipta). Our current study also 
focused on the comparative effectiveness of BDP/FF 
pMDI. Drug tolerability for BDP/FF pMDI may also be 
considered for the outcome of subsequent studies.
Conclusion
This study showed that in a real-life practice setting, the 
extrafine-formulation BDP/FF pMDI was found to be non-
inferior to both FP/SAL DPI and BDP/FF DPI in terms of 
the proportion of patients with COPD exacerbations within 
1-year after ICS/LABA combination/inhaler prescription. 
Lastly, within patients without a history of asthma, our 
results suggested that initiation of BDP/FF may be asso-
ciated with a lower proportion of patients with subsequent 
COPD exacerbations compared to initiation with FP/SAL.
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